{"nctId":"NCT01895452","briefTitle":"An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","startDateStruct":{"date":"2013-07"},"conditions":["Schizophrenia"],"count":291,"armGroups":[{"label":"ALKS 9072, Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 9072, Low Dose"]},{"label":"ALKS 9072, High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 9072, High Dose"]}],"interventions":[{"name":"ALKS 9072, Low Dose","otherNames":[]},{"name":"ALKS 9072, High Dose","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed the treatment period of Study ALK9072-003EXT\n* Continues to require chronic treatment with an antipsychotic medication\n* Continues to reside in a stable living situation\n* Continues to have an identified reliable informant\n\nExclusion Criteria:\n\n* Abnormal clinical laboratory value, vital sign, or electrocardiogram (ECG) finding during participation in Study ALK9072-003EXT that was clinically relevant and related to study drug\n* Missed more than 1 scheduled study visit during participation in the preceding Study ALK9072-003EXT\n* Has a significant or unstable medical condition that would preclude safe completion of the current study\n* Subject is pregnant or breastfeeding\n* Subject expects to be incarcerated, or has pending legal action which may impact compliance with study participation or procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs)","description":"This measure includes all incidences, including those that occurred \\>5%.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Baseline of Positive and Negative Syndrome Scale (PANSS) Total Score Over Time","description":"This scale consists of symptom constructs (7 positive, 7 negative, 16 general psychopathology), each to be rated on a 7-point Likert-type scale of severity with 1 being absent to 7 being extreme. Minimum scores (best outcome) equals 30 (total scale); maximum scores (worst outcome) equals 210 (total scale). Change is calculated between the baseline visit and the subject's last visit in the treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"6.73"},{"groupId":"OG001","value":"-0.9","spread":"6.07"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Clinical Global Impression - Severity (CGI-S) Over Time","description":"The CGI-S is a 7-point scale that requires the clinician to assess how mentally ill the patient is in a specific point in time. Results indicate participants evaluated at one of the following categories: \"1: normal, not at all ill\"; \"2: borderline mentally ill\"; \"3: mildly ill\"; \"4: moderately ill\"; \"5: markedly ill\"; \"6: severely ill\"; and \"7: among the most extremely ill patients\". Results indicate a change in CGI-S score from baseline to Day 365 based on the observed data. Change is calculated between the baseline visit and the subject's last visit in the treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.48"},{"groupId":"OG001","value":"-0.1","spread":"0.52"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Insomnia","Nasopharyngitis","Diarrhoea","Toothache"]}}}